First-in-human study of Hunteria umbellata seed extract (HSE-01) for early type 2 diabetes remission. Rigorous, FDA-aligned development creating an affordable, accessible path to diabetes reversal.
Novel alpha-glucosidase inhibitor from West African botanical. First-in-human trial of Hunteria umbellata with a unique intestinal glucose-blocking mechanism distinct from metformin and GLP-1 agonists.
Projected manufacturing cost <$50/month (97% cheaper than GLP-1 agonists). Designed for global access, with ethical benefit-sharing for West African communities whose traditional knowledge anchors this work.
Full 120-page protocol developed to ICH-GCP standards. FDA-aligned botanical drug pathway. Independent DSMB oversight. Transparent, reproducible, and registration-quality from day one.
After 12 months of intensive development, the HUNTER Trial (HSE-T2D-001) protocol is complete and undergoing final ClinicalTrials.gov registration. We have finalized a 120-page, IRB-ready clinical trial protocol, mapped the FDA botanical drug pathway, identified GMP manufacturing partners, and developed comprehensive safety monitoring frameworks.
We are now actively seeking: Principal Investigators (endocrinologists/clinical pharmacologists), clinical trial sites in Africa and globally, and funding partners committed to advancing affordable, evidence-based diabetes interventions.
Read Full AnnouncementWhether you're a clinical investigator, research institution, funding agency, or industry partner, we invite you to explore collaboration opportunities to bring HSE-01 from first-in-human trial to global impact.